A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients

被引：0

作者：

Tsirigotis, Panagiotis ^{[1
]}

Bitan, Reuven Or Menachem ^{[1
]}

Resnick, Igor B. ^{[1
]}

Samuel, Simcha ^{[1
]}

Ackerstein, Aliza ^{[1
]}

Elad, Sharon ^{[1
]}

Gesundheit, Benjamin ^{[1
]}

Zilberman, Irina ^{[1
]}

Miron, Svetlana ^{[1
]}

Leubovic, Alexander ^{[1
]}

Slavin, Shimon ^{[1
]}

Shapira, Michael Y. ^{[1
]}

机构：

[1] Hebrew Univ Jerusalem, Dept Bone Marrow Transplantat & Canc Immunotherap, Hadassah, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel

来源：

HAEMATOLOGICA | 2006年 / 91卷 / 06期

关键词：

allogeneic bone marrow transplantation; graft-versus-host disease; immunotherapy; elderly; co-morbidity;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe our experience with the use of a single non-myeloablative preparative regimen in stem cell transplantation (NST) in 37 heavily pretreated patients >= 55 years. The conditioning regimen consisted of fludarabine, low-dose busulfan, and antithymocyte globulin. Acute graft-versus-host disease (GVHD) grade III-IV and chronic GVHD developed in 15.6% and 44.4% of cases, respectively. With a median follow-up period of 22 (range 3-113) months, the 1-year overall survival and disease-free-survival rates were 55% and 53%, respectively, while the overall non-relapse mortality was 35%. In conclusion, reduced intensity stem cell transplantation is feasible and effective in patients >= 55 years. Age per se, should no longer be considered as a contra-indication to stem cell transplantation.

引用

页码：852 / 855

页数：4

共 14 条

[11] Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma [J].

Shimoni, A ;

Hardan, I ;

Avigdor, A ;

Yeshurun, M ;

Raanani, P ;

Ben-Bassat, I ;

Nagler, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) :457-464

[12] Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].

Slavin, S ;

Nagler, A ;

Naparstek, E ;

Kapelushnik, Y ;

Aker, M ;

Cividalli, G ;

Varadi, G ;

Kirschbaum, M ;

Ackerstein, A ;

Samuel, S ;

Amar, A ;

Brautbar, C ;

Ben-Tal, O ;

Eldor, A ;

Or, R .

BLOOD, 1998, 91 (03) :756-763

[13] Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years [J].

Wong, R ;

Giralt, SA ;

Martin, T ;

Couriel, DR ;

Anagnostopoulos, A ;

Hosing, C ;

Andersson, BS ;

Cano, P ;

Shahjahan, M ;

Ippoliti, C ;

Estey, EH ;

McMannis, J ;

Gajewski, JL ;

Champlin, RE ;

De Lima, M .

BLOOD, 2003, 102 (08) :3052-3059

[14] Allogeneic myeloablative transplantation for patients aged 50 years and over [J].

Yanada, M ;

Emi, N ;

Naoe, T ;

Sakamaki, H ;

Iseki, T ;

Hirabayashi, N ;

Karasuno, T ;

Chiba, S ;

Atsuta, Y ;

Hamajima, N ;

Takahashi, S ;

Kato, S .

BONE MARROW TRANSPLANTATION, 2004, 34 (01) :29-35

← 1 2 →